https://www.bioworld.com/rss en-us The EMA’s safety committee has issued a warning that the GLP-1 receptor agonist Ozempic (semaglutide, Novo Nordisk A/S) can cause an acute eye condition in which the optic nerve is damaged by a sudden loss of blood supply. After reviewing several large epidemiological studies, clinical trial and in-market data, EMA’s Pharmacovigilance Risk Assessment Committee has concluded non-anterior ischemic optic neuropathy is a “very rare” side effect of Ozempic, that “may affect up to one in 10,000 people taking semaglutide. http://www.bioworld.com/articles/720950 Fri, 06 Jun 2025 11:00:00 -0400 https://www.bioworld.com/articles/720950-ema-warns-ozempic-linked-to-very-rare-side-effect Ozempic pen and packaging Credit: Novo Nordisk A/S The EMA has started a review of Novo Nordisk A/S’ GLP-1 receptor agonist, semaglutide, after the Danish regulatory agency raised the possibility it causes an increased risk of suffering from an acute eye condition. After the first report in July 2024, the Danish regulator had received, by Dec. 10, 2024, a total of 19 reports of non-arteric anterior ischemic neuropathy, a rare condition that affects the small blood vessels at the front of the optic nerve. This can lead on to sudden vision loss and visual field defects. http://www.bioworld.com/articles/716383 Fri, 17 Jan 2025 12:00:00 -0500 https://www.bioworld.com/articles/716383-ema-investigating-potential-semaglutide-link-to-eye-disease The Danish Medicines Agency is to ask the EMA’s pharmacovigilance committee to investigate a potential increased risk of an acute eye condition in diabetic patients being treated with the glucagon-like peptide-1 receptor agonist Ozempic (semaglutide). http://www.bioworld.com/articles/715438 Tue, 17 Dec 2024 16:00:00 -0500 https://www.bioworld.com/articles/715438-danish-regulators-question-possible-ozempic-link-to-rare-eye-condition Ozempic pen and packaging Credit: Novo Nordisk A/S http://www.bioworld.com/articles/672504 Mon, 01 Jul 2019 00:00:00 -0400 https://www.bioworld.com/articles/672504-danish-medicines-agency-approves-aj-vaccines-polio-vaccine http://www.bioworld.com/articles/658130 Thu, 23 Mar 2017 00:00:00 -0400 https://www.bioworld.com/articles/658130-danish-clearance-for-oncology-venture-s-study-of-apo-010-in-multiple-myeloma http://www.bioworld.com/articles/631919 Fri, 08 Feb 2013 00:00:00 -0500 https://www.bioworld.com/articles/631919-avexxin-cleared-to-conduct-study-of-avx-001-in-denmark http://www.bioworld.com/articles/629516 Fri, 21 Sep 2012 00:00:00 -0400 https://www.bioworld.com/articles/629516-almirall-launches-aclidinium-in-europe http://www.bioworld.com/articles/618222 Thu, 09 Dec 2010 00:00:00 -0500 https://www.bioworld.com/articles/618222-first-european-approval-granted-for-sumavel-dosepro-for-migraine